SIGNIFICANT ACCOUNTING POLICIES

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES

a.	The accompanying unaudited interim consolidated financial statements for the three months periods ended March 31, 2019 and 2018 have been prepared in accordance with IAS 34 “Interim Financial Reporting” for interim financial information.

The interim consolidated financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Company's annual consolidated financial statements as of December 31, 2018 and their accompanying disclosures.

The interim consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the financial position, results of operations, and cash flows for the interim periods, but are not necessarily indicative of the results of operations to be anticipated for the full year ending December 31, 2019.

The accounting policies adopted in the preparation of the interim consolidated financial statements are consistent with those followed in the preparation of the company's annual consolidated financial statements for the year ended December 31, 2018, except for the adoption of new standards effective as of January 1, 2019. The Company has not early adopted any other standard, interpretation or amendment that has been issued but is not yet effective.

c.	IFRS 16 Leases:

The Company applies, for the first time, IFRS 16 Leases. As required by IAS 34, the nature and effect of these changes are disclosed below.

The Company adopted IFRS 16 using the modified retrospective method of adoption with the date of initial application of January 1, 2019. Under this method, the standard is applied retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial application. The Company elected to use the transition practical expedient allowing the standard to be applied only to contracts that were previously identified as leases applying IAS 17 and IFRIC 4 at the date of initial application. The Company also elected to use the recognition exemptions for lease contracts that, at the commencement date, have a lease term of 12 months or less and do not contain a purchase option (‘short-term leases’), and lease contracts for which the underlying asset is of low value (‘low-value assets’).

The Company has a number of lease contracts, mainly leases of an office building and a production plant. Before the adoption of IFRS 16, the Company classified each of its leases (as lessee) at the inception date as an operating lease. The leased property was not capitalized and the lease payments were recognized as rent expense in profit or loss on a straight-line basis over the lease term. Any prepaid rent and accrued rent were recognized under prepaid expenses and other current assets and accrued expenses and other payables, respectively.

Upon adoption of IFRS 16, the Company applied a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. The standard provides specific transition requirements and practical expedients, which has been applied by the Company.

The Company recognized right-of-use assets and lease liabilities for those leases previously classified as operating leases, except for short-term leases and leases of low-value assets. The right-of-use assets for most leases were recognised based on the carrying amount as if the standard had always been applied, apart from the use of incremental borrowing rate at the date of initial application. In some leases, the right-of-use assets were recognised based on the amount equal to the lease liabilities, adjusted for any related prepaid and accrued lease payments previously recognized. Lease liabilities were recognized based on the present value of the remaining lease payments, discounted using the incremental borrowing rate at the date of initial application.

Based on the foregoing, as at January 1, 2019:

•	Right-of-use assets of $7,106 were recognized and presented separately in the statement of financial position.

•	Additional lease liabilities of $7,032 were recognized and presented separately in the statement of financial position.

•	Prepaid expenses and other current assets of $256 and accrued expenses and other payables of $182 related to previous operating leases were derecognized.

Set out below, are the carrying amounts of the Company’s right-of-use assets and lease liabilities and the movements during the period:

	Right-of-use assets												Lease liabilities
	Offices and labs			Vehicles			Production Plant			Total			Lease liabilities
As of January 1, 2019	$	2,104		$	291		$	4,711		$	7,106		$	7,032
Depreciation expenses		(292	)		(32	)		(140	)		(464	)		—
Interest expenses		—			—			—			—			237
Re-measurement		—			—			26			26			26
Payments		—			—			—			—			(468	)
As of March 31, 2019	$	1,812		$	259		$	4,597		$	6,668		$	6,827

The lease liabilities as of January 1, 2019 reconciliation to the operating lease commitments as of December 31, 2018 are as follows:

Operating lease commitments as of December 31, 2018	$	7,441
Weighted average incremental borrowing rate as of January 1, 2019 (%)		1.42
Discounted operating lease commitments of January 1, 2019		7,032
Lease liabilities as of January 1, 2019	$	7,032

Set out below are the new accounting policies of the Company upon adoption of IFRS 16, which have been applied from the date of initial application:

a.	Right-of-use assets

The Company recognizes right-of-use assets at the commencement date of the lease (i.e., the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities

recognized, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received. Unless the Company is reasonably certain to obtain ownership of the leased asset at the end of the lease term, the recognized right-of-use assets are depreciated on a straight-line basis over the shorter of its estimated useful life and the lease term. Right-of- use assets are subject to impairment.

b.	Lease liabilities

At the commencement date of the lease, the Company recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including insubstance fixed payments) less any lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Company and payments of penalties for terminating a lease, if the lease term reflects the Company exercising the option to terminate. The variable lease payments that do not depend on an index or a rate are recognized as expense in the period in which the event or condition that triggers the payment occurs.

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES

The following accounting policies have been applied consistently in the financial statements for all periods presented, unless otherwise stated.

a.	Basis of presentation of the financial statements:

These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”).

The consolidated financial statements have been prepared on a cost basis, except for available-for-sale financial assets and financial liabilities that have been measured at fair value through profit or loss. The Company has elected to present profit or loss items using the function of expense method.

b.	The operating cycle of the Company is one year.

c.	Consolidated financial statements:

The consolidated financial statements comprise the financial statements of the Company and its Subsidiary.

The financial statements of the Company and its Subsidiary are prepared as of the same dates and periods. The consolidated financial statements are prepared using uniform accounting policies by all companies in the group. Significant intra-group balances, transactions and gains or losses resulting from intra-group are eliminated in full in the consolidated financial statements.

d.	Functional currency, presentation currency and foreign currency:

1.	Functional currency and presentation currency:

The presentation currency of the financial statements is the U.S. dollar.

The functional currency is the currency that best reflects the economic environment in which the Company and its Subsidiary operate and conduct their transactions. Most of the Company costs are incurred in U.S. dollars. In addition, the Company’s financing activities are incurred in U.S. dollars. The Company’s management believes that the functional currency of the Company is the U.S. dollar.

2.	Transactions, assets and liabilities in foreign currency:

Transactions denominated in foreign currency are recorded upon initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. Exchange rate differences are recognized in profit or loss. Non-monetary assets and liabilities measured at cost in foreign currency are translated at the exchange rate at the date of the transaction. Non-monetary assets and liabilities denominated in foreign currency and measured at fair value are translated into the functional currency using the exchange rate prevailing at the date when the fair value was determined.

e.	Cash equivalents:

Cash equivalents are considered as highly liquid investments, including unrestricted short-term bank deposits with an original maturity of three months or less from the date of investment or with a maturity of more than three months, but which are redeemable on demand without penalty and which form part of the Company’s cash management.

f.	Short-term deposits and restricted deposits:

Short-term bank deposits are deposits with an original maturity of more than three months from the date of investment and which do not meet the definition of cash equivalents. The deposits are presented according to their terms of deposit.

Restricted deposit is primarily invested in highly liquid deposits. Restricted deposit amounted to $150 and $0 as of December 31, 2018 and 2017, respectvley and is included in prepaid expenses and other current assets on the statements of financial position.

g.	Property and equipment:

Property, plant and equipment are measured at cost, including directly attributable costs, less accumulated depreciation, accumulated impairment losses and any related investment grants and excluding day-to-day servicing expenses.

Depreciation is calculated on a straight-line basis over the useful life of the assets at annual rates as follows:

	%
Machinery	15
Office furniture and equipment	6 - 33
Leasehold improvements	(*)

(*)	Leasehold improvements are depreciated on a straight-line basis over the shorter of the lease term (including the extension option held by the Company and intended to be exercised) and the expected life of the improvement.

The useful life, depreciation method and residual value of an asset are reviewed at least each year-end and any changes are accounted for prospectively as a change in accounting estimate.

An item of property and equipment is derecognized upon disposal or when no future economic benefits are expected from its use or disposal.

h.	Research and development costs:

Research expenditures are recognized in profit or loss when incurred. An intangible asset arising from a development project or from the development phase of an internal project is recognized if the Company can demonstrate: the technical feasibility of completing the intangible asset so that it will be available for use or sale; the Company’s intention to complete the intangible asset and use or sell it; the Company’s ability to use or sell the intangible asset; how the intangible asset will generate future economic benefits; the availability of adequate technical, financial and other resources to complete the intangible asset; and the Company’s ability to measure reliably the expenditure attributable to the intangible asset during its development. Since the Company’s development projects are often subject to regulatory approval procedures and other uncertainties, the conditions for the capitalization of costs incurred before receipt of approvals are not normally satisfied and, therefore, development expenditures are recognized in profit or loss when incurred.

i.	Impairment of non-financial assets:

The Company evaluates the need to record an impairment of the carrying amount of non-financial assets whenever events or changes in circumstances indicate that the carrying amount is not recoverable.

If the carrying amount of non-financial assets exceeds their recoverable amount, the assets are reduced to their recoverable amount. The recoverable amount is the higher of fair value less costs of sale and value in use. The recoverable amount of an asset that does not generate independent cash flows is determined for the cash-generating unit to which the asset belongs. Impairment losses are recognized in profit or loss.

An impairment loss of an asset is reversed only if there have been changes in the estimates used to determine the asset’s recoverable amount since the last impairment loss was recognized. Reversal of an impairment loss, as above, shall not be increased above the lower of the carrying amount that would have been determined (net of depreciation or amortization) had no impairment loss been recognized for the asset in prior years, and its recoverable amount.

During the years ended December 31, 2018, 2017 and 2016, the Company did not recognize any impairment of non-financial assets.

j.	Government investment grants:

Government grants are recognized when there is reasonable assurance that the grants will be received and the Company will comply with the related conditions.

Government grants received from Israel Innovation Authority (“IIA”) (formerly, the Office of the Chief Scientist in Israel (“OCS”)) are recognized upon receipt as a liability if future economic benefits are expected from the project that will result in royalty-bearing sales. If no such economic benefits are expected, the grants are recognized as a reduction of the related research and development expenses. In that event, the royalty obligation is treated as contingent liability in accordance with IAS 37.

At the end of each reporting period, the Company evaluates, based on its best estimate of future sales, whether there is reasonable assurance that the liability recognized, in whole or in part, will not be repaid (since the Company will not be required to pay royalties). If there is such reasonable assurance, the appropriate amount of the liability is derecognized and recorded in profit or loss as a revaluation of research and development expenses.

If the estimate of future sales indicates that there is no such reasonable assurance, the appropriate amount of the liability that reflects expected future royalty payments is recognized with a corresponding adjustment to financial expenses or income. As of December 31, 2018 and 2017, the Company determined that future economic benefits are expected from its research and development project and recorded a liability for its entire contingent obligation to IIA.

Grants received from the IIA which are recognized as a liability are accounted for as forgivable loans, in accordance with IAS 20 (Revised). Accordingly, when the liability for the loan is first recognized, it is measured at fair value using a discount rate that reflects a market rate of interest, which in the Company’s case was determined to be 28% and 25% for 2018 and 2017, respectively. The difference between the amount of the grants received and the fair value of the liability is accounted for upon recognition of the liability as a government grant and recognized as a reduction of research and development expenses.

For the years ended December 31, 2018, 2017 and 2016 no royalties were paid with respect to grants received from the IIA. Payments will be treated as a reduction of the liability.

Grants in the amount of $2,425, $2,948 and $4,264 were approved during 2018, 2017 and 2016, respectively. Grant receivable amounted to $0 and $1,578 as of December 31, 2018 and 2017, respectively, and is included in prepaid expenses and other current assets on the statements of financial position.

k.	Provisions:

A provision in accordance with IAS 37 is recognized when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation.

l.	Operating leases:

Lease agreements are classified as an operating lease if they do not transfer substantially all the risks and benefits incidental to ownership of the leased asset. Operating lease payments are recognized as an expense in profit or loss on a straight-line basis over the lease term.

m.	Share-based payment transactions:

The Company’s employees and other service providers are entitled to remuneration in the form of equity-settled share-based payment transactions.

Equity-settled transactions:

The cost of equity-settled transactions with employees is measured at the fair value of the equity instruments granted at grant date. The fair value is determined using an acceptable option pricing model.

With respect to other service providers, the cost of the transactions is measured at the fair value of the goods or services received as consideration for equity instruments. In cases where the fair value of the goods or services received as consideration of equity instruments cannot be measured, it is measured by reference to the fair value of the equity instruments granted.

The cost of equity-settled transactions is recognized in profit or loss, together with a corresponding increase in equity, during the period which the performance and/or service conditions are to be satisfied, ending on the date on which the relevant employee becomes fully entitled to the award.

No expense is recognized for awards that do not ultimately vest, except for awards where vesting is conditional upon a market condition, which are treated as vested irrespective of whether the market condition is satisfied, provided that all other vesting conditions are satisfied.

n.	Deferred tax:

Deferred tax is provided using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date.

Deferred tax assets are recognized for all deductible temporary differences. Deferred tax assets are recognized to the extent that it is probable that taxable profit will be available against which the deductible temporary differences and unused tax losses can be utilized.

Unrecognized deferred tax assets are re-assessed at each reporting date and are recognized to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.

o.	Employee benefit liabilities:

The Company has several employee benefit plans:

1.	Short-term employee benefits:

Short-term employee benefits are benefits that are expected to be settled entirely before twelve months after the end of the annual reporting period in which the employees render the related services. These benefits include salaries, paid annual leave, paid sick leave, recreation and social security contributions and are recognized as expenses as the services are rendered.

2.	Post-employment benefits:

The plans are normally financed by contributions to insurance companies and classified as defined benefit plans.

The Company operates a defined benefit plan in respect of severance pay pursuant to the Severance Pay Law, 1963 (the “Law”). According to the Law, employees are entitled to severance pay upon dismissal or retirement. The liability for termination of employment is measured using the projected unit credit method. The amounts are presented based on discounted expected future cash flows using a discount rate determined by reference to yields on Government bonds.

In respect of its severance pay obligation to certain of its employees, the Company makes current deposits in pension funds and insurance companies (the “Plan Assets”). Plan Assets comprise assets held by a long-term employee benefit fund or qualifying insurance policies. Plan Assets are not available to the Company’s own creditors and cannot be returned directly to the Company.

Actuarial gains and losses are recognized in other comprehensive income or (loss) retrospectively in the period in which they occur.

p.	Initial adoption of IFRS 9, “Financial Instruments”:

In July 2014, the IASB issued the final and complete version of IFRS 9, “Financial Instruments” (“the new Standard”), which replaces IAS 39, “Financial Instruments: Recognition and Measurement”. The new Standard mainly focuses on the classification and measurement of financial assets and it applies to all assets within the scope of IAS 39.

The new Standard has been applied for the first time in these financial statements retrospectively without restatement of comparative data.

There is no material effect of the initial adoption of the new Standard on the Company’s financial statements.

q.	Financial instruments:

As described in Note 2p regarding the initial adoption of IFRS 9, “Financial Instruments” (“the Standard”), the Company elected to adopt the provisions of the Standard retrospectively without restatement of comparative data.

The accounting policy for financial instruments applied until December 31, 2017, is as follows:

1.	Investment in marketable securities:

Financial assets within the scope of IAS 39 are initially recognized at fair value plus directly attributable transaction costs, except for financial assets measured at fair value through profit or loss in respect of which transaction costs are recorded in profit or loss.

After initial recognition, the accounting treatment of financial assets is based on their classification as follows:

a)	Financial assets at fair value through profit or loss

b)	Held-to-maturity investments

c)	Loans and receivables

d)	Available-for-sale financial assets

The Company classifies all of its marketable securities as available-for-sale. Available-for-sale financial assets are (non-derivative) financial assets that are designated as available for sale or are not classified in any of the three preceding categories. After initial recognition, available-for-sale financial assets are measured at fair value. Gains or losses from fair value adjustments, except for interest, exchange rate differences that relate to debt instruments and dividends from an equity instrument, are recognized in other comprehensive income. When the investment is disposed of or in case of impairment, the other comprehensive income (loss) is transferred to profit or loss.

Marketable securities as of December 31, 2017 and 2018 includes corporate and government debentures with no significant premium or discount. The investment in marketable securities which are classified as available-for-sale is considered Level 2 measurement.

2.	Financial liabilities:

Financial liabilities are recognized initially at fair value and, in the case of loans and borrowings and payables net of directly attribute transaction costs. The Company’s financial liabilities include trade and other payables and warrants to shareholders.

Warrants to shareholders can be excercied into a variable number of shares and therefore such warrants are recorded as a financial liability and are measured at each balance sheet date at their fair value. Gains or losses are recognized in profit or loss.

a)	Derecognition:

A financial liability is derecognized when the obligation under the liability is discharged or cancelled, or expires.

b)	Offsetting of financial instruments:

Financial assets and financial liabilities are offset and the net amount is reported in the statements of financial position if there is a currently enforceable legal right to offset the recognized amounts and there is an intention to settle on a net basis, to realize the assets and settle the liabilities simultaneously.

3.	Fair value:

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorized within the fair value hierarchy.

The carrying amounts of cash and cash equivalents, available-for-sale financial assets, other receivables, short-term deposits, and other current assets, trade payables and accrued expenses and other payables approximate their fair value due to the short-term maturity of such instruments. Regarding fair value of the liability to IIA, refer to note 2j above.

SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUPMTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS (FY)

12 Months Ended

Dec. 31, 2018

SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUPMTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS [Abstract]

SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUPMTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS

NOTE 3:- SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS

The key assumptions made in the financial statements concerning uncertainties at the end of the reporting period and the critical estimates computed by the Company that may result in a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.

-	Government grants:

Government grants received from the IIA at the Ministry of Industry, Trade and Labor are recognized as a liability if future economic benefits are expected from the research and development activity that will result in royalty-bearing sales. There is uncertainty regarding the estimated future cash flows and the estimated discount rate used to measure the amortized cost of the liability.

-	Determining the fair value of an unquoted financial liabilities:

The fair value of unquoted financial liabilities in Level 3 of the fair value hierarchy is determined using valuation techniques including projected cash flows discounted at current rates applicable for items with similar terms and risk characteristics. Changes in estimated projected cash flows and estimated discount rates, after consideration of risk factors such as liquidity risk, credit risk and volatility, are liable to affect the fair value of these liabilities.

DISCLOSURE OF NEW STANDARDS IN THE PERIOD PRIOR TO THEIR ADOPTION (FY)

12 Months Ended

Dec. 31, 2018

DISCLOSURE OF NEW STANDARDS IN THE PERIOD PRIOR TO THEIR ADOPTION [Abstract]

DISCLOSURE OF NEW STANDARDS IN THE PERIOD PRIOR TO THEIR ADOPTION

NOTE 4:- DISCLOSURE OF NEW STANDARDS IN THE PERIOD PRIOR TO THEIR ADOPTION

IFRS 16, “Leases”:

In January 2016, the IASB issued IFRS 16, “Leases” (“the new Lease Standard”). According to the new Lease Standard, a lease is a contract, or part of a contract, that conveys the right to use an asset for a period of time in exchange for consideration.

The effects of the adoption of the new Lease Standard are as follows:

•

According to the new Lease Standard, lessees are required to recognize all leases in the statement of financial position (excluding certain exceptions, see below). Lessees will recognize a liability for lease payments with a corresponding right-of-use asset, similar to the accounting treatment for finance leases under the existing standard, IAS 17, “Leases”. Lessees will also recognize interest expense and depreciation expense separately.

•	Variable lease payments that are not dependent on changes in the Consumer Price Index (“CPI”) or interest rates, but are based on performance or use are recognized as an expense by the lessees as incurred and recognized as income by the lessors as earned.

•	In the event of a change in variable lease payments that are CPI-linked, lessees are required to remeasure the lease liability and record the effect of the remeasurement as an adjustment to the carrying amount of the right-of-use asset.

•	The accounting treatment by lessors remains substantially unchanged from the existing standard, namely classification of a lease as a finance lease or an operating lease.

•	The new Lease Standard includes two exceptions which allow lessees to account for leases based on the existing accounting treatment for operating leases - leases for which the underlying asset is of low financial value and short-term leases (up to one year).

The new Lease Standard is effective for annual periods beginning on or after January 1, 2019.

The Company will apply the modified retrospective approach upon the initial adoption of the new Lease Standard by measuring the right-of-use asset at an amount equal to the lease liability, as measured on the transition date.

The Company has a number of lease contracts, mainly leases of an office building and a production plant (see also Note 9). In assessing the impact of the new Lease Standard on the financial statements, the Company evaluated the following matters:

•	Options to extend the lease - according to the new Lease Standard, the non-cancellable period of a lease includes periods that are covered by options to extend the lease if the lessee is reasonably certain to exercise the option.

•

Separation of lease components - according to the new Lease Standard, all lease components within a contract should be accounted for separately from non-lease components. A lessee is allowed a practical expedient according to which it can elect, by class of underlying asset, not to separate non-lease components from lease components, and instead account for them as a single lease component.

•	Incremental interest rate - the Company estimates the incremental interest rate to be used for measuring the lease liability and right-of-use asset on the date of initial adoption of the new Lease Standard, based on the lease term and nature of the leased asset.

The Company estimated that the effect of the initial adoption of the new Lease Standard as of January 1, 2019, is expected to result in an increase in the Company’s total assets and liabilities in the amount to $7,523 and no impact on equity.

Moreover, the effect of the initial adoption of the new Lease Standard in 2019 is expected to result in a decrease in the Company’s lease expenses of $1,940 and an increase in the Company’s depreciation and finance expenses of $1,928 and $94, respectively. The total effect of the initial adoption of the new Lease Standard in 2019 is expected to result in a decrease of $12 in operating loss and an increase of $82 in loss before income taxes.

CASH AND CASH EQUIVALENTS (FY)

12 Months Ended

Dec. 31, 2018

CASH AND CASH EQUIVALENTS [Abstract]

CASH AND CASH EQUIVALENTS

NOTE 5:- CASH AND CASH EQUIVALENTS

	December 31,
	2018		2017

Cash for immediate withdrawal	$	3,289	$	3,316
Cash equivalents - short-term deposits⁽¹⁾		36,983		18,009
	$	40,272	$	21,325

(1)	The cash equivalents are short-term bank deposits denominated in dollars and bear interest at an average annual rate of 2.05% and 1.050% as of December 31, 2018 and 2017, respectively.

PROPERTY AND EQUIPMENT, NET (FY)

12 Months Ended

Dec. 31, 2018

PROPERTY AND EQUIPMENT, NET [Abstract]

PROPERTY AND EQUIPMENT, NET

NOTE 6:- PROPERTY AND EQUIPMENT, NET

Composition and movement:

2018:

	Machinery		Office furniture and equipment		Leasehold improvements		Project in process		Total
Cost:

Balance at January 1, 2018	$	2,181	$	396	$	992	$	47	$	3,616
Additions		973		139		107		421		1,640

Balance at December 31, 2018		3,154		535		1,099		468		5,256

Accumulated depreciation:

Balance at January 1, 2018		1,558		308		810		—		2,676
Depreciation		195		37		37		—		269

Balance at December 31, 2018		1,753		345		847		—		2,945

Property and equipment, net at December 31, 2018	$	1,401	$	190	$	252	$	468	$	2,311

2017:

	Machinery		Office furniture and equipment		Leasehold improvements		Project in process		Total
Cost:

Balance at January 1, 2017	$	1,902	$	369	$	943	$	—	$	3,214
Additions		279		27		49		47		402

Balance at December 31, 2017		2,181		396		992		47		3,616

Accumulated depreciation:

Balance at January 1, 2017		1,433		292		789		—		2,514
Depreciation		125		16		21		—		162

Balance at December 31, 2017		1,558		308		810		—		2,676

Property and equipment, net at December 31, 2017	$	623	$	88	$	182	$	47	$	940

ACCRUED EXPENSES AND OTHER PAYABLES (FY)

12 Months Ended

Dec. 31, 2018

ACCRUED EXPENSES AND OTHER PAYABLES [Abstract]

ACCRUED EXPENSES AND OTHER PAYABLES

NOTE 7:- ACCRUED EXPENSES AND OTHER PAYABLES

	December 31,
	2018		2017
Subcontractors accruals	$	1,096	$	468
Legal and consulting accruals		479		201
Other		257		—
	$	1,832	$	669

LIABILITIES PRESENTED AT FAIR VALUE (FY)

3 Months Ended

12 Months Ended

Mar. 31, 2019

Dec. 31, 2018

LIABILITIES PRESENTED AT FAIR VALUE

NOTE 4:- LIABILITIES PRESENTED AT FAIR VALUE

a.	Warrants to purchase Company's shares:

The Company measured the fair value of the warrants by using Option Pricing Method utilized in a Black-Scholes simulation model. The option-pricing model requires a number of assumptions, of which the most significant are the expected stock price volatility and the expected time until liquidation. Expected volatility was calculated based upon historical volatilities of similar entities in the related sector index. The expected time until liquidation is the period in which liquidation event will occurred subject to the Company's expectations. The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends.

	Three months ended March 31,						December 31,
	2019			2018			2018
	Unaudited						Audited
Risk-free interest rate		2.21	%		2.3	%		2.52	%
Expected volatility		82	%		90	%		80	%
Expected life (in years)		3.25			2.25-3			3.5
Expected dividend yield		0			0			0

b.	Changes in the fair value of warrants classified as Level 3 in the fair value hierarchy:

	Fair value of financial derivatives
Balance at December 31, 2018	$	24,049
Exercise of warrants		(2,924	)
Revaluation of financial derivatives		3,906
Balance at March 31, 2019	$	25,031

NOTE 8:- LIABILITIES PRESENTED AT FAIR VALUE

a.	Warrants to purchase Preferred F-2 shares:

On June 18, 2017 the Company signed a Series F Preferred Share Purchase Agreement (“SPA”) with existing and new investors. According to the SPA and upon the closing that occurred on July 9, 2017 the Company issued 4,274,363 Preferred F-1 shares, nominal value NIS 0.01 each, at $9.44 per share, accompanied by the issuance of warrants to purchase 2,564,619 Preferred F-2 shares, nominal value NIS 0.01, with an exercise price of $11.33 per share, in exchange for an aggregate proceeds of $40,350. The issuance costs in the amount of $585 associated with the equity transaction have been charged directly to the consolidated statements of changes in equity and the issuance costs associated with the issuance of the warrants in the amount of $216 have been charged directly to the statement of comprehensive loss.

According to the SPA, the warrants to purchase Preferred F-2 Shares are subject to conversion ratio to be adjusted as defined in the SPA and to non-standard anti-dilution protection provisions and cashless exercise mechanism and therefore accounted for as a financial liability which was measured at fair value through profit or loss.

Upon the closing of the IPO as described in note 1b, 2,564,619 warrants to purchase Preferred F-2 shares were automatically converted into warrants to purchase 4,323,978 ordinary shares, nominal value NIS 0.01, with an exercise price of $6.72 per share with an expiration until earlier of July 3, 2022 or a Deemed Liquidation event as described in the Company’s articles of association (the “AOA”).

In December 2018, the Company issued a total of 293,489 ordinary shares pursuant to the cashless exercise of 607,044 warrants.

The Company measured the fair value of the warrants by using Black and Shoultz simulation model. The option-pricing model requires a number of assumptions, of which the most significant are the expected stock price volatility and the expected time until liquidation. Expected volatility was calculated based upon historical volatilities of similar entities in the related sector index. The expected time until liquidation is the period in which liquidation event will occurred subject to the Company’s expectations. The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends.

b.	Warrants to purchase Company’s shares:

	December 31,
	2018			2017
	Ordinary shares			Preferred F-2 shares
Risk-free interest rate		2.5	%		1.5	%
Expected volatility		80	%		90	%
Expected life (in years)		3.5			4.5
Expected dividend yield		0			0

c.	Changes in the fair value of warrants classified as Level 3 in the fair value hierarchy:

	Fair value of warrants E-2			Fair value of Warrants to purchase Ordinary shares			Total warrants presented at fair value
Balance at January 1, 2016	$	1,266		$	—		$	1,266

Revaluation of financial derivatives		(805	)		—			(805	)

Balance at December 31, 2016		461			—			461

Proceeds from issue of financial derivatives		—			10,900			10,900

Revaluation of financial derivatives		(461	)		(600	)		(1,061	)

Balance at December 31, 2017		—			10,300			10,300

Exercise of warrants		—			(3,851	)		(3,851	)

Revaluation of financial derivatives		—			17,600			17,600

Balance at December 31, 2018	$	—		$	24,049		$	24,049

d.	Description of significant unobservable inputs to valuation:

	December 31,
	2018		2017
	Preferred F-2 shares		Preferred F-2 shares
Sensitivity to changes in inputs:
Gain (loss) from change:
10% increase in volatility	$	—	$	720
10% decrease in volatility	$	—	$	(750	)

Gain (loss) from change:
1% increase in discount rate	$	—	$	(1,040	)
1% decrease in discount rate	$	—	$	(1,290	)

CONTINGENT LIABILITIES AND COMMITMENTS (FY)

12 Months Ended

Dec. 31, 2018

CONTINGENT LIABILITIES AND COMMITMENTS [Abstract]

CONTINGENT LIABILITIES AND COMMITMENTS

NOTE 9:- CONTINGENT LIABILITIES AND COMMITMENTS

The Company has entered into commercial real estate lease agreements which consist of the office building and production plant. The leases are under non-cancellable terms and mature over 1-9 years. In December 2017, the Company signed a lease agreement for a production plant which will be effective upon fulfillment of the suspending condition as described in the lease agreement.

The future minimum lease fees payable as of December 31, 2018 are as follows:

First year	$	1,803
Second through fifth years		2,522
After fifth year		2,395
	$	6,720

b.	The Company rents vehicles under an operating lease agreement, for a fixed monthly fee of $13. The leases are under non-cancellable terms and mature over 1-3 years.

The Company is obligated to pay royalties to the Government of Israel through the IIA at the rates of 3% to 4% on sales proceeds from products developed through the grants received from the IIA. The maximum amount of royalties payable to the Government of Israel is limited to 100% of the grants received, linked to the dollar and bearing interest at the LIBOR rate. The obligation to pay these royalties is contingent on actual sales of the products and in the absence of such sales, no payment is required. The Company expects to incur sales that will trigger payments of royalties starting in 2020. As of December 31, 2018, the Company’s aggregate contingent obligations for payments to the IIA, based on royalty-bearing participation received or accrued amounted to $34,197 (including interest of $4,916).

SHAREHOLDERS' EQUITY (FY)

12 Months Ended

Dec. 31, 2018

SHAREHOLDERS' EQUITY [Abstract]

SHAREHOLDERS' EQUITY

NOTE 10:- SHAREHOLDERS’ EQUITY

a.	Composition of share capital:

	December 31,
	2018				2017
	Authorized		Issued and outstanding		Authorized		Issued and outstanding
	Number of shares
Ordinary share of NIS 0.01 par value		100,000,000		24,930,736		22,007,000		549,990
Ordinary B share of NIS 0.01 par value		—		—		140,000		139,908
Ordinary C share of NIS 0.01 par value		—		—		1,130,000		—
		100,000,000		24,930,736		23,277,000		689,898

	December 31,
	2018				2017
	Authorized		Issued and outstanding		Authorized		Issued and outstanding
	Number of shares
Series Preferred A share of NIS 0.01 par value		—		—		600,000		600,000
Series Preferred B share of NIS 0.01 par value		—		—		1,454,000		1,453,846
Series Preferred C share of NIS 0.01 par value		—		—		2,828,000		2,827,430
Series Preferred D share of NIS 0.01 par value		—		—		3,405,000		3,404,314
Series Preferred E1 share of NIS 0.01 par value		—		—		572,000		571,478
Series Preferred E2 share of NIS 0.01 par value		—		—		1,024,000		1,023,312
Series Preferred F1 share of NIS 0.01 par value		—		—		4,275,000		4,274,363
Series Preferred F2 share of NIS 0.01 par value		—		—		2,565,000		—
		—		—		16,723,000		14,154,743

b.	Rights attached to the shares:

1.	Ordinary shares:

Subject to our current AOA, the holders of ordinary shares have the right to receive notices to attend and vote in general meetings of the Company’s shareholders, and the right to share in dividends and other distributions and upon liquidation.

2.	Preferred shares:

All issued and outstanding preferred shares were converted to ordinary shares upon the IPO.

SHARE-BASED PAYMENT (FY)

3 Months Ended

12 Months Ended

Mar. 31, 2019

Dec. 31, 2018

SELECTED STATEMENTS OF COMPREHENSIVE LOSS DATA [Abstract]

SHARE-BASED PAYMENT

NOTE 3:- SHARE-BASED PAYMENT

The total compensation cost related to all of the Company's equity-based awards, recognized during the presented periods was comprised as follows:

	Three months ended March 31,				Year ended December 31,
	2019		2018		2018
	Unaudited
Research and development	$	229	$	482	$	705
General and administrative		862		362		2,870
	$	1,091	$	844	$	3,575

The Company estimates the fair value of stock options granted using the Binominal option-pricing model. The option-pricing model requires a number of assumptions, of which the most significant are the expected stock price volatility and the expected option term.

Expected volatility was calculated based upon historical volatilities of similar entities in the related sector index. The expected term of the options granted is derived from output of the option valuation model and represents the period of time that options granted are expected to be outstanding. The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends.

The following table lists the inputs to the binomial model used for the fair value measurement of equity-settled share options for the above plan for the following periods:

Based on the above inputs, the fair value of the options was determined at $10.50 - $11.01 at the grant dates during 2019.

	Three months ended March 31,						December 31,
	2019			2018			2018
	Unaudited						Audited
Dividend yield (%)		0			0			0
Expected volatility of the share prices (%)		76%-80	%		88%-94	%		93%-95	%
Risk-free interest rate (%)		2.51-2.70			2.17-2.89			2.63-2.88

Movement during the periods:

	Three months ended March 31,									Year ended December 31, 2018
	2019				2018					Year ended December 31, 2018
	Number of options		Weighted average exercise price		Number of options			Weighted average exercise price		Number of options			Weighted average exercise price
			USD					USD					USD
Outstanding at beginning of period		3,197,616		3.07		2,467,023			2.28		2,467,023			2.28
Granted during the period		544,800		10.93		—			—		751,977			5.60
Expired during the period		—		—		—			—		(2,000	)		6.00
Exercised during the period		—		—		—			—		(9,692	)		0.25
Forfeited during the period		—		—		(9,692	)		0.25		(9,692	)		0.25
Share options outstanding at end of period		3,742,416		3.63		2,457,331			2.27		3,197,616			3.07
Share options exercisable at end of period		1,755,342		1.37		1,428,275			0.74		1,705,256			1.21

As of March 31, 2019, there are $7,851 of total unrecognized cost related to non-vested share based compensation that are expected to be recognized over a period of up to 4 years.

NOTE 11:- SHARE-BASED PAYMENT

On November 23, 2014, the Company’s Board of Directors approved, subject to the approval of the shareholders, the creation of a new class of shares of the Company, Ordinary C shares, nominal value NIS 0.01 each and to classify 1,500,000 ordinary shares for such class, 1,152,044 out of which for allocation to the Company’s employees under the new amended 2014 Israel Share Option Plan (“2014 Plan”). The exercise price of the options granted under the plans may not be less than the nominal value of the shares into which the options are exercised. The options vest primarily over three years. Any options, which are forfeited or not exercised before expiration, become available for future grants.

There are no cash settlement alternatives. On December 29, 2014, the Company’s shareholders meeting ratified and approved the aforesaid decisions.

On January 23, 2017 the Company’s Board of Directors approved the Company’s 2017 Share Incentive Plan (the “2017 Plan”), and the subsequent grant of options to the Company’s employees, officers and directors. Pursuant to the Plan, the Company initially

reserved for issuance 312,867 ordinary shares, nominal value NIS 0.01 each. Contemporaneously, the Company’s Board of Directors approved the termination of the Company’s 2014 Plan and the extension of the exercise period of the outstanding options to Ordinary C shares to expire on January 2020 instead of January 2018. There was no material impact on the financial statements, with respect to the Company’s 2014 plan extension. On February 28, 2017 the Company’s shareholders approved the 2017 Plan.

On June 26, 2017 and on December 28, 2017 the Company’s Board of Directors approved the reservation of additional 463,384 and 559,764 ordinary shares, respectively, for issuance under the 2017 Plan (totaling, including previous plans, an aggregate of 1,338,015 ordinary shares).

The following table lists the inputs to the binomial model used for the fair value measurement of equity-settled share options for the above plan for years 2018, 2017 and 2016:

	Year ended December 31,
	2018			2017			2016
Dividend yield (%)		0			0			0
Expected volatility of the share prices (%)		93%-95	%		89%-94	%		71%-94	%
Risk-free interest rate (%)		2.63-2.88			1.76-2.4			0.3
Share price	$	8.00		$	5.00		$	13.4

Based on the above inputs, the fair value of the options was determined at $3.64-$5.85 at the grant date.

b.	Movement during the year:

	2018				2017
	Number of options		Weighted average exercise price		Number of options		Weighted average exercise price
			USD				USD
Outstanding at beginning of year		2,467,023		2.28		1,129,008		0.25
Granted during the year		751,977		5.60		1,338,015		3.99
Expired during the period		2,000		6.00		—		—
Exercised during the period		9,692		0.25		—		—
Forfeited during the year		9,692		0.25		—		—

Share options outstanding at end of year		3,197,616		3.07		2,467,023		2.28
Share options exercisable at end of year		1,705,256		1.21		1,379,075		0.60

c.	As of December 31, 2018, there are $4,103 of total unrecognized company cost related to non-vested share based compensation that are expected to be recognized over a period of up to 4 years.

TAXES ON INCOME (FY)

12 Months Ended

Dec. 31, 2018

TAXES ON INCOME [Abstract]

TAXES ON INCOME

NOTE 12:- TAXES ON INCOME

a.	Tax rates applicable to the income of the Company:

1)	Corporate Tax rates:

Taxable income of the Israeli parent is subject to the Israeli corporate tax at the rate of 25% in 2016, 24% in 2017 and 23% in 2018.

Non-Israeli subsidiaries are taxed according to the tax laws in their respective countries of residence.

2)	Income subject to tax benefits under the Law for the Encouragement of Capital Investments, 1959 (the “Investment Law”):

The Investment Law provides tax benefits for Israeli companies meeting certain requirements and criteria. The Investment Law has undergone certain amendments and reforms in recent years.

The Israeli parliament enacted a reform to the Investment Law, effective January 2011. According to the reform, a flat rate tax applies to companies eligible for the “Preferred Enterprise” status. In order to be eligible for Preferred Enterprise status, a company must meet minimum requirements to establish that it contributes to the country’s economic growth and is a competitive factor for the gross domestic product.

The Company’s Israeli operations elected “Preferred Enterprise” status, starting in 2017.

Benefits granted to a Preferred Enterprise include reduced tax rates. In peripheral regions (Development Area A) the reduced tax rate was 9% in 2016. As part of Economic Efficiency Law (Legislative Amendments for Accomplishment of Budgetary Targets for Budget Years 2017-2018), 5777-2016, the tax rate for Area A will be 7.5% in 2017 onwards. In other regions the tax rate is 16%. Preferred Enterprises in peripheral regions will be eligible for Investment Center grants, as well as the applicable reduced tax rates.

b.	The Law for the Encouragement of Industry (Taxation), 1969:

The Company has the status of an “industrial company”, under this law. According to this status and by virtue of regulations published thereunder, the Company is entitled to claim a deduction of accelerated depreciation on equipment used in industrial activities, as determined in the regulations issued under the Inflationary Law. The Company is also entitled to amortize a patent or a patent or knowhow usage right that are used in the enterprise’s development or promotion, to deduct listed share issuance expenses and to file consolidated financial statements under certain conditions.

c.	Net operating losses carryforward:

The Company has net operating losses and capital loss for tax purposes as of December 31, 2018, in the amount of $120,000 and $500, respectively, which may be carried forward and offset against taxable income in the future for an indefinite period.

d.	Final tax assessments:

The Company’s tax assessments through the 2012 tax year are considered final.

e.	Deferred taxes:

The Company did not recognize deferred tax assets in the Company’s consolidated financial statements for the years ended December 31, 2018 and 2017 for carryforward losses and other temporary differences because their utilization in the foreseeable future is not probable.

SELECTED STATEMENTS OF COMPREHENSIVE LOSS DATA (FY)

12 Months Ended

Dec. 31, 2018

SELECTED STATEMENTS OF COMPREHENSIVE LOSS DATA

NOTE 13:- SELECTED STATEMENTS OF COMPREHENSIVE INCOME DATA

a.	Research and development expenses, net:

	Year ended December 31,
	2018			2017			2016
Salaries and social benefits	$	5,016		$	3,795		$	2,774
Share-based payment		705			1,362			3,195
Subcontractors		12,695			9,617			8,150
Materials		3,610			1,677			2,232
Rent and maintenance		758			486			364
Travel and trade shows		728			346			507
Depreciation		195			142			124
Other		239			—			61
Less royalty bearing grants		(1,901	)		(2,407	)		(4,030	)
Reversal of grants received in prior years to related liability		—			—			5,718

Total research and development expenses, net	$	22,045		$	15,018		$	19,095

b.	General and administrative expenses:

	Year ended December 31,
	2018		2017		2016
Salaries and social benefits	$	4,788	$	1,870	$	924
Share-based payment		2,870		846		2,647
Professional services		2,818		1,467		843
Rent and maintenance		1,065		83		138
Other		58		206		62

Total general and administrative expenses	$	11,599	$	4,472	$	4,614

c.	Finance expenses:

	Year ended December 31,
	2018		2017		2016
Revaluation of IIA liability	$	2,037	$	631	$	—
Revaluation of liabilities at fair value		17,600		—		—
Bank charges, interest expense and other fees		68		54		23
Foreign currency translation adjustments		554		33		132

Total finance expenses	$	20,259	$	718	$	155

d.	Finance income:

	Year ended December 31,
	2018		2017		2016
Interest income	$	877	$	330	$	163
Revaluation of liabilities at fair value		—		845		805
Foreign currency translation adjustments	$	165		22		225

Total finance income	$	1,042	$	1,197	$	1,193

RELATED PARTY TRANSACTIONS (FY)

12 Months Ended

Dec. 31, 2018

RELATED PARTY TRANSACTIONS

NOTE 14:- RELATED PARTY TRANSACTIONS

Benefits to key executive personnel:

	December 31,
	2018		2017		2016
Short-term benefits	$	1,921	$	1,578	$	987
Other long-term benefits		63		569		61
Share-based payment		2,342		1,689		4,842
	$	4,326	$	3,836	$	5,890

GENERAL (Q1)

3 Months Ended

12 Months Ended

Mar. 31, 2019

Dec. 31, 2018

GENERAL [Abstract]

GENERAL

NOTE 1:- GENERAL

a.	Gamida Cell Ltd. (the “Company”), founded in 1998, is a clinical-stage biopharmaceutical company that develops novel curative treatments for orphan indications, including hematologicalmalignancies and rare genetic diseases using stem cells and Natural Killer (NK) cells.

b.	The Company uses its proprietary platform NAM technology to expand in culture, highly functional cells derived from umbilical cord blood or peripheral blood, while enhancing the potential therapeutic efficacy of these cells.

Omidubicel was granted a Breakthrough Therapy designation from the FDA and an orphan drug designation in the US and in Europe.

d.	Definitions:

In these financial statements:

The Company	-	Gamida Cell Ltd. and its subsidiary

Subsidiary		Gamida Cell Inc. Incorporated in 2000 and intended to focus on sales and marketing upon product approval.

Related Parties	-	As defined in IAS 24

Dollar	-	U.S. dollar

NOTE 1:- GENERAL

a.	Gamida Cell Ltd. (the “Company”), founded in 1998, is a clinical-stage biopharmaceutical company that develops novel curative treatments for orphan indications, including hematological malignancies and rare genetic diseases using stem cells and natural killer (NK) cells.

c.	The Company uses its proprietary platform NAM technology to expand in culture, highly functional cells derived from umbilical cord blood or peripheral blood, while enhancing the potential therapeutic efficacy of these cells.

Omidubicel was granted Breakthrough Therapy designation from the FDA and Orphan Drug designation in the US and in Europe.

e.	Definitions:

In these financial statements:

The Company	-	Gamida Cell Ltd. and its Subsidiary

Subsidiary	-	Gamida Cell Inc. Incorporated in 2000 and intended to focus on sales and marketing upon product approval

Related Parties	-	As defined in IAS 24

Dollar	-	U.S. dollar

SIGNIFICANT ACCOUNTING POLICIES (Q1)

3 Months Ended

12 Months Ended

Mar. 31, 2019

Dec. 31, 2018

SIGNIFICANT ACCOUNTING POLICIES

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES

a.	The accompanying unaudited interim consolidated financial statements for the three months periods ended March 31, 2019 and 2018 have been prepared in accordance with IAS 34 “Interim Financial Reporting” for interim financial information.

c.	IFRS 16 Leases:

The Company applies, for the first time, IFRS 16 Leases. As required by IAS 34, the nature and effect of these changes are disclosed below.

Based on the foregoing, as at January 1, 2019:

•	Right-of-use assets of $7,106 were recognized and presented separately in the statement of financial position.

•	Additional lease liabilities of $7,032 were recognized and presented separately in the statement of financial position.

•	Prepaid expenses and other current assets of $256 and accrued expenses and other payables of $182 related to previous operating leases were derecognized.

Set out below, are the carrying amounts of the Company’s right-of-use assets and lease liabilities and the movements during the period:

	Right-of-use assets												Lease liabilities
	Offices and labs			Vehicles			Production Plant			Total			Lease liabilities
As of January 1, 2019	$	2,104		$	291		$	4,711		$	7,106		$	7,032
Depreciation expenses		(292	)		(32	)		(140	)		(464	)		—
Interest expenses		—			—			—			—			237
Re-measurement		—			—			26			26			26
Payments		—			—			—			—			(468	)
As of March 31, 2019	$	1,812		$	259		$	4,597		$	6,668		$	6,827

The lease liabilities as of January 1, 2019 reconciliation to the operating lease commitments as of December 31, 2018 are as follows:

Operating lease commitments as of December 31, 2018	$	7,441
Weighted average incremental borrowing rate as of January 1, 2019 (%)		1.42
Discounted operating lease commitments of January 1, 2019		7,032
Lease liabilities as of January 1, 2019	$	7,032

Set out below are the new accounting policies of the Company upon adoption of IFRS 16, which have been applied from the date of initial application:

a.	Right-of-use assets

b.	Lease liabilities

NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES

The following accounting policies have been applied consistently in the financial statements for all periods presented, unless otherwise stated.

a.	Basis of presentation of the financial statements:

b.	The operating cycle of the Company is one year.

c.	Consolidated financial statements:

The consolidated financial statements comprise the financial statements of the Company and its Subsidiary.

d.	Functional currency, presentation currency and foreign currency:

1.	Functional currency and presentation currency:

The presentation currency of the financial statements is the U.S. dollar.

2.	Transactions, assets and liabilities in foreign currency:

e.	Cash equivalents:

f.	Short-term deposits and restricted deposits:

g.	Property and equipment:

Depreciation is calculated on a straight-line basis over the useful life of the assets at annual rates as follows:

	%
Machinery	15
Office furniture and equipment	6 - 33
Leasehold improvements	(*)

(*)	Leasehold improvements are depreciated on a straight-line basis over the shorter of the lease term (including the extension option held by the Company and intended to be exercised) and the expected life of the improvement.

The useful life, depreciation method and residual value of an asset are reviewed at least each year-end and any changes are accounted for prospectively as a change in accounting estimate.

An item of property and equipment is derecognized upon disposal or when no future economic benefits are expected from its use or disposal.

h.	Research and development costs:

i.	Impairment of non-financial assets:

The Company evaluates the need to record an impairment of the carrying amount of non-financial assets whenever events or changes in circumstances indicate that the carrying amount is not recoverable.

During the years ended December 31, 2018, 2017 and 2016, the Company did not recognize any impairment of non-financial assets.

j.	Government investment grants:

Government grants are recognized when there is reasonable assurance that the grants will be received and the Company will comply with the related conditions.

For the years ended December 31, 2018, 2017 and 2016 no royalties were paid with respect to grants received from the IIA. Payments will be treated as a reduction of the liability.

k.	Provisions:

l.	Operating leases:

m.	Share-based payment transactions:

The Company’s employees and other service providers are entitled to remuneration in the form of equity-settled share-based payment transactions.

Equity-settled transactions:

n.	Deferred tax:

o.	Employee benefit liabilities:

The Company has several employee benefit plans:

1.	Short-term employee benefits:

2.	Post-employment benefits:

The plans are normally financed by contributions to insurance companies and classified as defined benefit plans.

Actuarial gains and losses are recognized in other comprehensive income or (loss) retrospectively in the period in which they occur.

p.	Initial adoption of IFRS 9, “Financial Instruments”:

The new Standard has been applied for the first time in these financial statements retrospectively without restatement of comparative data.

There is no material effect of the initial adoption of the new Standard on the Company’s financial statements.

q.	Financial instruments:

The accounting policy for financial instruments applied until December 31, 2017, is as follows:

1.	Investment in marketable securities:

After initial recognition, the accounting treatment of financial assets is based on their classification as follows:

a)	Financial assets at fair value through profit or loss

b)	Held-to-maturity investments

c)	Loans and receivables

d)	Available-for-sale financial assets

2.	Financial liabilities:

a)	Derecognition:

A financial liability is derecognized when the obligation under the liability is discharged or cancelled, or expires.

b)	Offsetting of financial instruments:

3.	Fair value:

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorized within the fair value hierarchy.

SHARE-BASED PAYMENT (Q1)

3 Months Ended

12 Months Ended

Mar. 31, 2019

Dec. 31, 2018

SHARE-BASED PAYMENT

NOTE 3:- SHARE-BASED PAYMENT

The total compensation cost related to all of the Company's equity-based awards, recognized during the presented periods was comprised as follows:

	Three months ended March 31,				Year ended December 31,
	2019		2018		2018
	Unaudited
Research and development	$	229	$	482	$	705
General and administrative		862		362		2,870
	$	1,091	$	844	$	3,575

The following table lists the inputs to the binomial model used for the fair value measurement of equity-settled share options for the above plan for the following periods:

Based on the above inputs, the fair value of the options was determined at $10.50 - $11.01 at the grant dates during 2019.

	Three months ended March 31,						December 31,
	2019			2018			2018
	Unaudited						Audited
Dividend yield (%)		0			0			0
Expected volatility of the share prices (%)		76%-80	%		88%-94	%		93%-95	%
Risk-free interest rate (%)		2.51-2.70			2.17-2.89			2.63-2.88

Movement during the periods:

	Three months ended March 31,									Year ended December 31, 2018
	2019				2018					Year ended December 31, 2018
	Number of options		Weighted average exercise price		Number of options			Weighted average exercise price		Number of options			Weighted average exercise price
			USD					USD					USD
Outstanding at beginning of period		3,197,616		3.07		2,467,023			2.28		2,467,023			2.28
Granted during the period		544,800		10.93		—			—		751,977			5.60
Expired during the period		—		—		—			—		(2,000	)		6.00
Exercised during the period		—		—		—			—		(9,692	)		0.25
Forfeited during the period		—		—		(9,692	)		0.25		(9,692	)		0.25
Share options outstanding at end of period		3,742,416		3.63		2,457,331			2.27		3,197,616			3.07
Share options exercisable at end of period		1,755,342		1.37		1,428,275			0.74		1,705,256			1.21

As of March 31, 2019, there are $7,851 of total unrecognized cost related to non-vested share based compensation that are expected to be recognized over a period of up to 4 years.

NOTE 11:- SHARE-BASED PAYMENT

There are no cash settlement alternatives. On December 29, 2014, the Company’s shareholders meeting ratified and approved the aforesaid decisions.

The following table lists the inputs to the binomial model used for the fair value measurement of equity-settled share options for the above plan for years 2018, 2017 and 2016:

	Year ended December 31,
	2018			2017			2016
Dividend yield (%)		0			0			0
Expected volatility of the share prices (%)		93%-95	%		89%-94	%		71%-94	%
Risk-free interest rate (%)		2.63-2.88			1.76-2.4			0.3
Share price	$	8.00		$	5.00		$	13.4

Based on the above inputs, the fair value of the options was determined at $3.64-$5.85 at the grant date.

b.	Movement during the year:

	2018				2017
	Number of options		Weighted average exercise price		Number of options		Weighted average exercise price
			USD				USD
Outstanding at beginning of year		2,467,023		2.28		1,129,008		0.25
Granted during the year		751,977		5.60		1,338,015		3.99
Expired during the period		2,000		6.00		—		—
Exercised during the period		9,692		0.25		—		—
Forfeited during the year		9,692		0.25		—		—

Share options outstanding at end of year		3,197,616		3.07		2,467,023		2.28
Share options exercisable at end of year		1,705,256		1.21		1,379,075		0.60

c.	As of December 31, 2018, there are $4,103 of total unrecognized company cost related to non-vested share based compensation that are expected to be recognized over a period of up to 4 years.

LIABILITIES PRESENTED AT FAIR VALUE (Q1)

3 Months Ended

12 Months Ended

Mar. 31, 2019

Dec. 31, 2018

LIABILITIES PRESENTED AT FAIR VALUE

NOTE 4:- LIABILITIES PRESENTED AT FAIR VALUE

a.	Warrants to purchase Company's shares:

	Three months ended March 31,						December 31,
	2019			2018			2018
	Unaudited						Audited
Risk-free interest rate		2.21	%		2.3	%		2.52	%
Expected volatility		82	%		90	%		80	%
Expected life (in years)		3.25			2.25-3			3.5
Expected dividend yield		0			0			0

b.	Changes in the fair value of warrants classified as Level 3 in the fair value hierarchy:

	Fair value of financial derivatives
Balance at December 31, 2018	$	24,049
Exercise of warrants		(2,924	)
Revaluation of financial derivatives		3,906
Balance at March 31, 2019	$	25,031

NOTE 8:- LIABILITIES PRESENTED AT FAIR VALUE

a.	Warrants to purchase Preferred F-2 shares:

In December 2018, the Company issued a total of 293,489 ordinary shares pursuant to the cashless exercise of 607,044 warrants.

b.	Warrants to purchase Company’s shares:

	December 31,
	2018			2017
	Ordinary shares			Preferred F-2 shares
Risk-free interest rate		2.5	%		1.5	%
Expected volatility		80	%		90	%
Expected life (in years)		3.5			4.5
Expected dividend yield		0			0

c.	Changes in the fair value of warrants classified as Level 3 in the fair value hierarchy:

	Fair value of warrants E-2			Fair value of Warrants to purchase Ordinary shares			Total warrants presented at fair value
Balance at January 1, 2016	$	1,266		$	—		$	1,266

Revaluation of financial derivatives		(805	)		—			(805	)

Balance at December 31, 2016		461			—			461

Proceeds from issue of financial derivatives		—			10,900			10,900

Revaluation of financial derivatives		(461	)		(600	)		(1,061	)

Balance at December 31, 2017		—			10,300			10,300

Exercise of warrants		—			(3,851	)		(3,851	)

Revaluation of financial derivatives		—			17,600			17,600

Balance at December 31, 2018	$	—		$	24,049		$	24,049

d.	Description of significant unobservable inputs to valuation:

	December 31,
	2018		2017
	Preferred F-2 shares		Preferred F-2 shares
Sensitivity to changes in inputs:
Gain (loss) from change:
10% increase in volatility	$	—	$	720
10% decrease in volatility	$	—	$	(750	)

Gain (loss) from change:
1% increase in discount rate	$	—	$	(1,040	)
1% decrease in discount rate	$	—	$	(1,290	)

SIGNIFICANT ACCOUNTING POLICIES (FY) (Policies)

3 Months Ended

12 Months Ended

Mar. 31, 2019

Dec. 31, 2018

Basis of presentation of the financial statements

a.	The accompanying unaudited interim consolidated financial statements for the three months periods ended March 31, 2019 and 2018 have been prepared in accordance with IAS 34 “Interim Financial Reporting” for interim financial information.

a.	Basis of presentation of the financial statements:

b.	The operating cycle of the Company is one year.

Consolidated financial statements

c.	Consolidated financial statements:

The consolidated financial statements comprise the financial statements of the Company and its Subsidiary.

Functional currency, presentation currency and foreign currency

d.	Functional currency, presentation currency and foreign currency:

1.	Functional currency and presentation currency:

The presentation currency of the financial statements is the U.S. dollar.

2.	Transactions, assets and liabilities in foreign currency:

Cash equivalents

e.	Cash equivalents:

Short-term deposits and restricted deposits

f.	Short-term deposits and restricted deposits:

Property and equipment

g.	Property and equipment:

Depreciation is calculated on a straight-line basis over the useful life of the assets at annual rates as follows:

	%
Machinery	15
Office furniture and equipment	6 - 33
Leasehold improvements	(*)

(*)	Leasehold improvements are depreciated on a straight-line basis over the shorter of the lease term (including the extension option held by the Company and intended to be exercised) and the expected life of the improvement.

The useful life, depreciation method and residual value of an asset are reviewed at least each year-end and any changes are accounted for prospectively as a change in accounting estimate.

An item of property and equipment is derecognized upon disposal or when no future economic benefits are expected from its use or disposal.

Research and development costs

h.	Research and development costs:

Impairment of non-financial assets

i.	Impairment of non-financial assets:

The Company evaluates the need to record an impairment of the carrying amount of non-financial assets whenever events or changes in circumstances indicate that the carrying amount is not recoverable.

During the years ended December 31, 2018, 2017 and 2016, the Company did not recognize any impairment of non-financial assets.

Government investment grants

j.	Government investment grants:

Government grants are recognized when there is reasonable assurance that the grants will be received and the Company will comply with the related conditions.

For the years ended December 31, 2018, 2017 and 2016 no royalties were paid with respect to grants received from the IIA. Payments will be treated as a reduction of the liability.

Provisions

k.	Provisions:

Operating leases

c.	IFRS 16 Leases:

The Company applies, for the first time, IFRS 16 Leases. As required by IAS 34, the nature and effect of these changes are disclosed below.

Based on the foregoing, as at January 1, 2019:

•	Right-of-use assets of $7,106 were recognized and presented separately in the statement of financial position.

•	Additional lease liabilities of $7,032 were recognized and presented separately in the statement of financial position.

•	Prepaid expenses and other current assets of $256 and accrued expenses and other payables of $182 related to previous operating leases were derecognized.

Set out below, are the carrying amounts of the Company’s right-of-use assets and lease liabilities and the movements during the period:

	Right-of-use assets												Lease liabilities
	Offices and labs			Vehicles			Production Plant			Total			Lease liabilities
As of January 1, 2019	$	2,104		$	291		$	4,711		$	7,106		$	7,032
Depreciation expenses		(292	)		(32	)		(140	)		(464	)		—
Interest expenses		—			—			—			—			237
Re-measurement		—			—			26			26			26
Payments		—			—			—			—			(468	)
As of March 31, 2019	$	1,812		$	259		$	4,597		$	6,668		$	6,827

The lease liabilities as of January 1, 2019 reconciliation to the operating lease commitments as of December 31, 2018 are as follows:

Operating lease commitments as of December 31, 2018	$	7,441
Weighted average incremental borrowing rate as of January 1, 2019 (%)		1.42
Discounted operating lease commitments of January 1, 2019		7,032
Lease liabilities as of January 1, 2019	$	7,032

Set out below are the new accounting policies of the Company upon adoption of IFRS 16, which have been applied from the date of initial application:

a.	Right-of-use assets

b.	Lease liabilities

l.	Operating leases:

Share-based payment transactions

m.	Share-based payment transactions:

The Company’s employees and other service providers are entitled to remuneration in the form of equity-settled share-based payment transactions.

Equity-settled transactions:

Deferred tax

n.	Deferred tax:

Employee benefit liabilities

o.	Employee benefit liabilities:

The Company has several employee benefit plans:

1.	Short-term employee benefits:

2.	Post-employment benefits:

The plans are normally financed by contributions to insurance companies and classified as defined benefit plans.

Actuarial gains and losses are recognized in other comprehensive income or (loss) retrospectively in the period in which they occur.

Initial adoption of IFRS 9, "Financial Instruments"

p.	Initial adoption of IFRS 9, “Financial Instruments”:

The new Standard has been applied for the first time in these financial statements retrospectively without restatement of comparative data.

There is no material effect of the initial adoption of the new Standard on the Company’s financial statements.

Financial instruments

q.	Financial instruments:

The accounting policy for financial instruments applied until December 31, 2017, is as follows:

1.	Investment in marketable securities:

After initial recognition, the accounting treatment of financial assets is based on their classification as follows:

a)	Financial assets at fair value through profit or loss

b)	Held-to-maturity investments

c)	Loans and receivables

d)	Available-for-sale financial assets

2.	Financial liabilities:

a)	Derecognition:

A financial liability is derecognized when the obligation under the liability is discharged or cancelled, or expires.

b)	Offsetting of financial instruments:

3.	Fair value:

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorized within the fair value hierarchy.

SIGNIFICANT ACCOUNTING POLICIES (Q1) (Policies)

3 Months Ended

12 Months Ended

Mar. 31, 2019

Dec. 31, 2018

Basis of presentation of the financial statements

a.	The accompanying unaudited interim consolidated financial statements for the three months periods ended March 31, 2019 and 2018 have been prepared in accordance with IAS 34 “Interim Financial Reporting” for interim financial information.

a.	Basis of presentation of the financial statements:

b.	The operating cycle of the Company is one year.

IFRS 16 Leases

c.	IFRS 16 Leases:

The Company applies, for the first time, IFRS 16 Leases. As required by IAS 34, the nature and effect of these changes are disclosed below.

Based on the foregoing, as at January 1, 2019:

•	Right-of-use assets of $7,106 were recognized and presented separately in the statement of financial position.

•	Additional lease liabilities of $7,032 were recognized and presented separately in the statement of financial position.

•	Prepaid expenses and other current assets of $256 and accrued expenses and other payables of $182 related to previous operating leases were derecognized.

Set out below, are the carrying amounts of the Company’s right-of-use assets and lease liabilities and the movements during the period:

	Right-of-use assets												Lease liabilities
	Offices and labs			Vehicles			Production Plant			Total			Lease liabilities
As of January 1, 2019	$	2,104		$	291		$	4,711		$	7,106		$	7,032
Depreciation expenses		(292	)		(32	)		(140	)		(464	)		—
Interest expenses		—			—			—			—			237
Re-measurement		—			—			26			26			26
Payments		—			—			—			—			(468	)
As of March 31, 2019	$	1,812		$	259		$	4,597		$	6,668		$	6,827

The lease liabilities as of January 1, 2019 reconciliation to the operating lease commitments as of December 31, 2018 are as follows:

Operating lease commitments as of December 31, 2018	$	7,441
Weighted average incremental borrowing rate as of January 1, 2019 (%)		1.42
Discounted operating lease commitments of January 1, 2019		7,032
Lease liabilities as of January 1, 2019	$	7,032

Set out below are the new accounting policies of the Company upon adoption of IFRS 16, which have been applied from the date of initial application:

a.	Right-of-use assets

b.	Lease liabilities

l.	Operating leases:

SIGNIFICANT ACCOUNTING POLICIES (FY) (Tables)

12 Months Ended

Dec. 31, 2018

Estimated Useful Life of Property and Equipment

Depreciation is calculated on a straight-line basis over the useful life of the assets at annual rates as follows:

	%
Machinery	15
Office furniture and equipment	6 - 33
Leasehold improvements	(*)

(*)	Leasehold improvements are depreciated on a straight-line basis over the shorter of the lease term (including the extension option held by the Company and intended to be exercised) and the expected life of the improvement.

CASH AND CASH EQUIVALENTS (FY) (Tables)

12 Months Ended

Dec. 31, 2018

CASH AND CASH EQUIVALENTS [Abstract]

Information About Cash and Cash Equivalents

	December 31,
	2018		2017

Cash for immediate withdrawal	$	3,289	$	3,316
Cash equivalents - short-term deposits⁽¹⁾		36,983		18,009
	$	40,272	$	21,325

(1)	The cash equivalents are short-term bank deposits denominated in dollars and bear interest at an average annual rate of 2.05% and 1.050% as of December 31, 2018 and 2017, respectively.

PROPERTY AND EQUIPMENT, NET (FY) (Tables)

12 Months Ended

Dec. 31, 2018

PROPERTY AND EQUIPMENT, NET [Abstract]

Property and Equipment, Net

Composition and movement:

2018:

	Machinery		Office furniture and equipment		Leasehold improvements		Project in process		Total
Cost:

Balance at January 1, 2018	$	2,181	$	396	$	992	$	47	$	3,616
Additions		973		139		107		421		1,640

Balance at December 31, 2018		3,154		535		1,099		468		5,256

Accumulated depreciation:

Balance at January 1, 2018		1,558		308		810		—		2,676
Depreciation		195		37		37		—		269

Balance at December 31, 2018		1,753		345		847		—		2,945

Property and equipment, net at December 31, 2018	$	1,401	$	190	$	252	$	468	$	2,311

2017:

	Machinery		Office furniture and equipment		Leasehold improvements		Project in process		Total
Cost:

Balance at January 1, 2017	$	1,902	$	369	$	943	$	—	$	3,214
Additions		279		27		49		47		402

Balance at December 31, 2017		2,181		396		992		47		3,616

Accumulated depreciation:

Balance at January 1, 2017		1,433		292		789		—		2,514
Depreciation		125		16		21		—		162

Balance at December 31, 2017		1,558		308		810		—		2,676

Property and equipment, net at December 31, 2017	$	623	$	88	$	182	$	47	$	940

ACCRUED EXPENSES AND OTHER PAYABLES (FY) (Tables)

12 Months Ended

Dec. 31, 2018

ACCRUED EXPENSES AND OTHER PAYABLES [Abstract]

Accrued Expenses and Other Payables

	December 31,
	2018		2017
Subcontractors accruals	$	1,096	$	468
Legal and consulting accruals		479		201
Other		257		—
	$	1,832	$	669

LIABILITIES PRESENTED AT FAIR VALUE (FY) (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2019

Dec. 31, 2018

Warrants to Purchase Preferred Shares

	Three months ended March 31,						December 31,
	2019			2018			2018
	Unaudited						Audited
Risk-free interest rate		2.21	%		2.3	%		2.52	%
Expected volatility		82	%		90	%		80	%
Expected life (in years)		3.25			2.25-3			3.5
Expected dividend yield		0			0			0

b.	Warrants to purchase Company’s shares:

	December 31,
	2018			2017
	Ordinary shares			Preferred F-2 shares
Risk-free interest rate		2.5	%		1.5	%
Expected volatility		80	%		90	%
Expected life (in years)		3.5			4.5
Expected dividend yield		0			0

Changes in the Fair Value of Warrants

b.	Changes in the fair value of warrants classified as Level 3 in the fair value hierarchy:

	Fair value of financial derivatives
Balance at December 31, 2018	$	24,049
Exercise of warrants		(2,924	)
Revaluation of financial derivatives		3,906
Balance at March 31, 2019	$	25,031

c.	Changes in the fair value of warrants classified as Level 3 in the fair value hierarchy:

	Fair value of warrants E-2			Fair value of Warrants to purchase Ordinary shares			Total warrants presented at fair value
Balance at January 1, 2016	$	1,266		$	—		$	1,266

Revaluation of financial derivatives		(805	)		—			(805	)

Balance at December 31, 2016		461			—			461

Proceeds from issue of financial derivatives		—			10,900			10,900

Revaluation of financial derivatives		(461	)		(600	)		(1,061	)

Balance at December 31, 2017		—			10,300			10,300

Exercise of warrants		—			(3,851	)		(3,851	)

Revaluation of financial derivatives		—			17,600			17,600

Balance at December 31, 2018	$	—		$	24,049		$	24,049

Description of Significant Unobservable Inputs to Valuation

d.	Description of significant unobservable inputs to valuation:

	December 31,
	2018		2017
	Preferred F-2 shares		Preferred F-2 shares
Sensitivity to changes in inputs:
Gain (loss) from change:
10% increase in volatility	$	—	$	720
10% decrease in volatility	$	—	$	(750	)

Gain (loss) from change:
1% increase in discount rate	$	—	$	(1,040	)
1% decrease in discount rate	$	—	$	(1,290	)

CONTINGENT LIABILITIES AND COMMITMENTS (FY) (Tables)

12 Months Ended

Dec. 31, 2018

CONTINGENT LIABILITIES AND COMMITMENTS [Abstract]

Future Minimum Lease Fees Payable

The future minimum lease fees payable as of December 31, 2018 are as follows:

First year	$	1,803
Second through fifth years		2,522
After fifth year		2,395
	$	6,720

SHAREHOLDERS' EQUITY (FY) (Tables)

12 Months Ended

Dec. 31, 2018

SHAREHOLDERS' EQUITY [Abstract]

Composition of Share Capital

a.	Composition of share capital:

	December 31,
	2018				2017
	Authorized		Issued and outstanding		Authorized		Issued and outstanding
	Number of shares
Ordinary share of NIS 0.01 par value		100,000,000		24,930,736		22,007,000		549,990
Ordinary B share of NIS 0.01 par value		—		—		140,000		139,908
Ordinary C share of NIS 0.01 par value		—		—		1,130,000		—
		100,000,000		24,930,736		23,277,000		689,898

	December 31,
	2018				2017
	Authorized		Issued and outstanding		Authorized		Issued and outstanding
	Number of shares
Series Preferred A share of NIS 0.01 par value		—		—		600,000		600,000
Series Preferred B share of NIS 0.01 par value		—		—		1,454,000		1,453,846
Series Preferred C share of NIS 0.01 par value		—		—		2,828,000		2,827,430
Series Preferred D share of NIS 0.01 par value		—		—		3,405,000		3,404,314
Series Preferred E1 share of NIS 0.01 par value		—		—		572,000		571,478
Series Preferred E2 share of NIS 0.01 par value		—		—		1,024,000		1,023,312
Series Preferred F1 share of NIS 0.01 par value		—		—		4,275,000		4,274,363
Series Preferred F2 share of NIS 0.01 par value		—		—		2,565,000		—
		—		—		16,723,000		14,154,743

SHARE-BASED PAYMENT (FY) (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2019

Dec. 31, 2018

Fair Value Measurement of Equity-Settled Share Options

Based on the above inputs, the fair value of the options was determined at $10.50 - $11.01 at the grant dates during 2019.

	Three months ended March 31,						December 31,
	2019			2018			2018
	Unaudited						Audited
Dividend yield (%)		0			0			0
Expected volatility of the share prices (%)		76%-80	%		88%-94	%		93%-95	%
Risk-free interest rate (%)		2.51-2.70			2.17-2.89			2.63-2.88

The following table lists the inputs to the binomial model used for the fair value measurement of equity-settled share options for the above plan for years 2018, 2017 and 2016:

	Year ended December 31,
	2018			2017			2016
Dividend yield (%)		0			0			0
Expected volatility of the share prices (%)		93%-95	%		89%-94	%		71%-94	%
Risk-free interest rate (%)		2.63-2.88			1.76-2.4			0.3
Share price	$	8.00		$	5.00		$	13.4

Stock Option Activity

Movement during the periods:

	Three months ended March 31,									Year ended December 31, 2018
	2019				2018					Year ended December 31, 2018
	Number of options		Weighted average exercise price		Number of options			Weighted average exercise price		Number of options			Weighted average exercise price
			USD					USD					USD
Outstanding at beginning of period		3,197,616		3.07		2,467,023			2.28		2,467,023			2.28
Granted during the period		544,800		10.93		—			—		751,977			5.60
Expired during the period		—		—		—			—		(2,000	)		6.00
Exercised during the period		—		—		—			—		(9,692	)		0.25
Forfeited during the period		—		—		(9,692	)		0.25		(9,692	)		0.25
Share options outstanding at end of period		3,742,416		3.63		2,457,331			2.27		3,197,616			3.07
Share options exercisable at end of period		1,755,342		1.37		1,428,275			0.74		1,705,256			1.21

b.	Movement during the year:

	2018				2017
	Number of options		Weighted average exercise price		Number of options		Weighted average exercise price
			USD				USD
Outstanding at beginning of year		2,467,023		2.28		1,129,008		0.25
Granted during the year		751,977		5.60		1,338,015		3.99
Expired during the period		2,000		6.00		—		—
Exercised during the period		9,692		0.25		—		—
Forfeited during the year		9,692		0.25		—		—

Share options outstanding at end of year		3,197,616		3.07		2,467,023		2.28
Share options exercisable at end of year		1,705,256		1.21		1,379,075		0.60

SELECTED STATEMENTS OF COMPREHENSIVE LOSS DATA (FY) (Tables)

12 Months Ended

Dec. 31, 2018

SELECTED STATEMENTS OF COMPREHENSIVE LOSS DATA [Abstract]

Research and Development Expenses, Net

a.	Research and development expenses, net:

	Year ended December 31,
	2018			2017			2016
Salaries and social benefits	$	5,016		$	3,795		$	2,774
Share-based payment		705			1,362			3,195
Subcontractors		12,695			9,617			8,150
Materials		3,610			1,677			2,232
Rent and maintenance		758			486			364
Travel and trade shows		728			346			507
Depreciation		195			142			124
Other		239			—			61
Less royalty bearing grants		(1,901	)		(2,407	)		(4,030	)
Reversal of grants received in prior years to related liability		—			—			5,718

Total research and development expenses, net	$	22,045		$	15,018		$	19,095

General and Administrative Expenses

b.	General and administrative expenses:

	Year ended December 31,
	2018		2017		2016
Salaries and social benefits	$	4,788	$	1,870	$	924
Share-based payment		2,870		846		2,647
Professional services		2,818		1,467		843
Rent and maintenance		1,065		83		138
Other		58		206		62

Total general and administrative expenses	$	11,599	$	4,472	$	4,614

Finance Expenses

c.	Finance expenses:

	Year ended December 31,
	2018		2017		2016
Revaluation of IIA liability	$	2,037	$	631	$	—
Revaluation of liabilities at fair value		17,600		—		—
Bank charges, interest expense and other fees		68		54		23
Foreign currency translation adjustments		554		33		132

Total finance expenses	$	20,259	$	718	$	155

Finance Income

d.	Finance income:

	Year ended December 31,
	2018		2017		2016
Interest income	$	877	$	330	$	163
Revaluation of liabilities at fair value		—		845		805
Foreign currency translation adjustments	$	165		22		225

Total finance income	$	1,042	$	1,197	$	1,193

RELATED PARTY TRANSACTIONS (FY) (Tables)

12 Months Ended

Dec. 31, 2018

Benefits to Key Executive Personnel

Benefits to key executive personnel:

	December 31,
	2018		2017		2016
Short-term benefits	$	1,921	$	1,578	$	987
Other long-term benefits		63		569		61
Share-based payment		2,342		1,689		4,842
	$	4,326	$	3,836	$	5,890

SIGNIFICANT ACCOUNTING POLICIES (Q1) (Tables)

3 Months Ended

Mar. 31, 2019

Carrying Amounts of Right-of-Use Assets and Lease Liabilities

Set out below, are the carrying amounts of the Company’s right-of-use assets and lease liabilities and the movements during the period:

	Right-of-use assets												Lease liabilities
	Offices and labs			Vehicles			Production Plant			Total			Lease liabilities
As of January 1, 2019	$	2,104		$	291		$	4,711		$	7,106		$	7,032
Depreciation expenses		(292	)		(32	)		(140	)		(464	)		—
Interest expenses		—			—			—			—			237
Re-measurement		—			—			26			26			26
Payments		—			—			—			—			(468	)
As of March 31, 2019	$	1,812		$	259		$	4,597		$	6,668		$	6,827

Reconciliation of Operating Lease Commitments

The lease liabilities as of January 1, 2019 reconciliation to the operating lease commitments as of December 31, 2018 are as follows:

Operating lease commitments as of December 31, 2018	$	7,441
Weighted average incremental borrowing rate as of January 1, 2019 (%)		1.42
Discounted operating lease commitments of January 1, 2019		7,032
Lease liabilities as of January 1, 2019	$	7,032

SHARE-BASED PAYMENT (Q1) (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2019

Dec. 31, 2018

Compensation Related Costs

The total compensation cost related to all of the Company's equity-based awards, recognized during the presented periods was comprised as follows:

	Three months ended March 31,				Year ended December 31,
	2019		2018		2018
	Unaudited
Research and development	$	229	$	482	$	705
General and administrative		862		362		2,870
	$	1,091	$	844	$	3,575

Fair Value Measurement of Equity-Settled Share Options

Based on the above inputs, the fair value of the options was determined at $10.50 - $11.01 at the grant dates during 2019.

	Three months ended March 31,						December 31,
	2019			2018			2018
	Unaudited						Audited
Dividend yield (%)		0			0			0
Expected volatility of the share prices (%)		76%-80	%		88%-94	%		93%-95	%
Risk-free interest rate (%)		2.51-2.70			2.17-2.89			2.63-2.88

The following table lists the inputs to the binomial model used for the fair value measurement of equity-settled share options for the above plan for years 2018, 2017 and 2016:

	Year ended December 31,
	2018			2017			2016
Dividend yield (%)		0			0			0
Expected volatility of the share prices (%)		93%-95	%		89%-94	%		71%-94	%
Risk-free interest rate (%)		2.63-2.88			1.76-2.4			0.3
Share price	$	8.00		$	5.00		$	13.4

Stock Option Activity

Movement during the periods:

	Three months ended March 31,									Year ended December 31, 2018
	2019				2018					Year ended December 31, 2018
	Number of options		Weighted average exercise price		Number of options			Weighted average exercise price		Number of options			Weighted average exercise price
			USD					USD					USD
Outstanding at beginning of period		3,197,616		3.07		2,467,023			2.28		2,467,023			2.28
Granted during the period		544,800		10.93		—			—		751,977			5.60
Expired during the period		—		—		—			—		(2,000	)		6.00
Exercised during the period		—		—		—			—		(9,692	)		0.25
Forfeited during the period		—		—		(9,692	)		0.25		(9,692	)		0.25
Share options outstanding at end of period		3,742,416		3.63		2,457,331			2.27		3,197,616			3.07
Share options exercisable at end of period		1,755,342		1.37		1,428,275			0.74		1,705,256			1.21

b.	Movement during the year:

	2018				2017
	Number of options		Weighted average exercise price		Number of options		Weighted average exercise price
			USD				USD
Outstanding at beginning of year		2,467,023		2.28		1,129,008		0.25
Granted during the year		751,977		5.60		1,338,015		3.99
Expired during the period		2,000		6.00		—		—
Exercised during the period		9,692		0.25		—		—
Forfeited during the year		9,692		0.25		—		—

Share options outstanding at end of year		3,197,616		3.07		2,467,023		2.28
Share options exercisable at end of year		1,705,256		1.21		1,379,075		0.60

LIABILITIES PRESENTED AT FAIR VALUE (Q1) (Tables)

3 Months Ended

12 Months Ended

Mar. 31, 2019

Dec. 31, 2018

Warrants to Purchase Preferred Shares

	Three months ended March 31,						December 31,
	2019			2018			2018
	Unaudited						Audited
Risk-free interest rate		2.21	%		2.3	%		2.52	%
Expected volatility		82	%		90	%		80	%
Expected life (in years)		3.25			2.25-3			3.5
Expected dividend yield		0			0			0

b.	Warrants to purchase Company’s shares:

	December 31,
	2018			2017
	Ordinary shares			Preferred F-2 shares
Risk-free interest rate		2.5	%		1.5	%
Expected volatility		80	%		90	%
Expected life (in years)		3.5			4.5
Expected dividend yield		0			0

Changes in Fair Value of Warrants

b.	Changes in the fair value of warrants classified as Level 3 in the fair value hierarchy:

	Fair value of financial derivatives
Balance at December 31, 2018	$	24,049
Exercise of warrants		(2,924	)
Revaluation of financial derivatives		3,906
Balance at March 31, 2019	$	25,031

c.	Changes in the fair value of warrants classified as Level 3 in the fair value hierarchy:

	Fair value of warrants E-2			Fair value of Warrants to purchase Ordinary shares			Total warrants presented at fair value
Balance at January 1, 2016	$	1,266		$	—		$	1,266

Revaluation of financial derivatives		(805	)		—			(805	)

Balance at December 31, 2016		461			—			461

Proceeds from issue of financial derivatives		—			10,900			10,900

Revaluation of financial derivatives		(461	)		(600	)		(1,061	)

Balance at December 31, 2017		—			10,300			10,300

Exercise of warrants		—			(3,851	)		(3,851	)

Revaluation of financial derivatives		—			17,600			17,600

Balance at December 31, 2018	$	—		$	24,049		$	24,049

GENERAL (FY) (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		12 Months Ended
	Oct. 30, 2018	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Equity [Abstract]
Net proceeds from IPO			$ 0	$ 47,479	$ 0	$ 0
Conversion of preferred shares (in shares)	(17,289,289)
Accumulated deficits		$ (184,720)	(123,673)	(169,213)	(116,282)
Cash flows from operating activities		$ (9,450)	$ (6,799)	$ (26,426)	$ (16,549)	$ (12,590)
Initial Public Offering [Member]
Equity [Abstract]
Ordinary shares sold (in shares)	6,250,000
Share price (in dollars per share)	$ 8
Net proceeds from IPO	$ 47,241
Issuance costs related to equity	$ 5,947
Underwriters [Member]
Equity [Abstract]
Ordinary shares sold (in shares)	398,368

SIGNIFICANT ACCOUNTING POLICIES (FY) (Details) - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Short-term deposits and restricted deposits [Abstract]

Restricted deposit

$ 150

$ 0

Impairment of non-financial assets [Abstract]

Impairment of non-financial assets

$ 0

Government investment grants [Abstract]

Discount rate on grants

28.00%

25.00%

Royalties paid with respect to grants received

$ 0

Grants approved

2,425

2,948

$ 4,264

Grant receivable

$ 0

$ 1,578

Machinery [Member]

Office Furniture and Equipment [Member] | Bottom of Range [Member]

15.00%

Office Furniture and Equipment [Member] | Top of Range [Member]

6.00%

Leasehold Improvements [Member]

33.00%